Protagonist Therapeutics (NASDAQ: PTGX) and Pluristem Therapeutics (NASDAQ:PSTI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Profitability

This table compares Protagonist Therapeutics and Pluristem Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Protagonist Therapeutics N/A -64.21% -50.51%
Pluristem Therapeutics N/A -100.14% -80.04%

Insider & Institutional Ownership

39.7% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 4.3% of Pluristem Therapeutics shares are held by institutional investors. 15.5% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 7.0% of Pluristem Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Protagonist Therapeutics and Pluristem Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Protagonist Therapeutics N/A N/A -$37.17 million ($2.69) -6.75
Pluristem Therapeutics $2.85 million 52.35 -$27.81 million ($0.32) -4.31

Pluristem Therapeutics has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Pluristem Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Protagonist Therapeutics and Pluristem Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protagonist Therapeutics 0 0 2 0 3.00
Pluristem Therapeutics 0 0 4 0 3.00

Protagonist Therapeutics presently has a consensus target price of $39.50, indicating a potential upside of 117.51%. Pluristem Therapeutics has a consensus target price of $4.38, indicating a potential upside of 217.03%. Given Pluristem Therapeutics’ higher possible upside, analysts plainly believe Pluristem Therapeutics is more favorable than Protagonist Therapeutics.

Volatility and Risk

Protagonist Therapeutics has a beta of -1.66, meaning that its stock price is 266% less volatile than the S&P 500. Comparatively, Pluristem Therapeutics has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500.

Summary

Pluristem Therapeutics beats Protagonist Therapeutics on 6 of the 10 factors compared between the two stocks.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn’s disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s products include PLX-PAD and PLX R18. The Company’s PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company’s PLX products are administered using a standard needle and syringe. The Company’s PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women’s health diseases.

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.